Typhax
The typhoid fever vaccine market is valued at $200 million per year. Existing commercial typhoid fever vaccines have clear limitations.
Pneumococcal Vaccine Candidate MVX01
Pneumococcal Protective Protein Antigen vaccine candidate - our universal approach to combat pneumococcal disease.
C. difficile Vaccine Candidate MVX02
C. difficile infections results in 14,000 deaths per year in the United States. Matrivax is targeting the pathogen and the toxoids.
​
Vaccines targeting high-impact bacterial diseases
1. WHO, 2014; 2. WHO, 2000; 3. WHO, 2005; 4. CDC, 2013
Contact Us
650 Albany Street, Suite 117, Boston, MA 02118
inquiry@matrivax.com | Tel: 617-358-7640